Israel’s Teva Pharmaceutical has received marketing authorisation from the European Commission (EC) for Ajovy (fremanezumab), an injection intended to provide relief from migraines.

Adults who suffer at least four migraine days per month will be eligible to be treated with the drug, a 225mg solution in a pre-filled syringe.

Ajovy is a humanised monoclonal antibody (mAb) that targets and binds to the calcitonin gene-related peptide (CGRP) ligand. The drug prevents the ligand’s binding to the receptor.

Data from two pivotal Phase III clinical trials of fremanezumab as a prophylactic treatment showed a significant decrease in migraine days, compared to a placebo. These trials enrolled adults with disabling migraines.

Fremanezumab-related adverse drug reactions (ADRs) observed during the studies were mostly short-term flare ups in the skin around the injection site, such as pain, hardening, redness, itching and rash.

“Migraine can have a significant impact on the day-to-day life of patients with some experiencing 15 headache days per month.”

Ajovy is available in quarterly, as well as monthly dosing options, depending in the individual needs of patients. The quarterly dose is administered as three subcutaneous injections, which allows 675mg of the drug into the bloodstream.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Teva Pharmaceutical European Commercial executive vice-president Richard Daniell said: “Migraine can have a significant impact on the day-to-day life of patients with some experiencing 15 headache days per month.

“It is our hope that Ajovy will provide patients and European healthcare professionals with a preventive treatment, which offers patients more migraine free days, as well as greater flexibility in managing this unpredictable disease.”

The approval is applicable to all 28 European Union (EU) member states, as well as Iceland, Norway and Liechtenstein.

Teva received positive recommendation from the European Medicines Agency (EMA) panel in February this year to grant a marketing approval for the drug.

In September last year, the US Food and Drug Administration (FDA) approved the drug for the preventive treatment of migraine in adults with disabling migraines.